2026-04-17T10:22:14Zhttps://recercat.cat/oai/requestoai:recercat.cat:10256/214922024-06-18T12:38:15Zcom_2072_452955com_2072_2054col_2072_453068
RECERCAT
author
Font, Rebeca
author
Buxó Pujolràs, Maria
author
Ameijide, Alberto
author
Martínez, José Miguel
author
Marcos-Gragera, Rafael
author
Carulla, Marià
author
Puigdemont, Montserrat
author
Vilardell, Mireia
author
Civit, Sergi
author
Viñas, Gemma
author
Espinàs, Josep Alfons
author
Galceran, Jaume
author
Izquierdo i Font, Àngel Xavier
author
Borràs, Josep M.
author
Clèries, Ramon
2024-06-18T12:38:15Z
2024-06-18T12:38:15Z
2022-05-16
http://hdl.handle.net/10256/21492
We show how the use and interpretation of population-based cancer survival indicators can help oncologists talk with breast cancer (BC) patients about the relationship between their prognosis and their adherence to endocrine therapy (ET). The study population comprised a population-based cohort of estrogen receptor positive BC patients (N = 1268) diagnosed in Girona and Tarragona (Northeastern Spain) and classified according to HER2 status (+ / −), stage at diagnosis (I/II/III) and five-year cumulative adherence rate (adherent > 80%; non-adherent ≤ 80%). Cox regression analysis was performed to identify significant prognostic factors for overall survival, whereas relative survival (RS) was used to estimate the crude probability of death due to BC (PBC). Stage and adherence to ET were the significant factors for predicting all-cause mortality. Compared to stage I, risk of death increased in stage II (hazard ratio [HR] 2.24, 95% confidence interval [CI]: 1.51–3.30) and stage III (HR 5.11, 95% CI 3.46–7.51), and it decreased with adherence to ET (HR 0.57, 95% CI 0.41–0.59). PBC differences were higher in non-adherent patients compared to adherent ones and increased across stages: stage I: 6.61% (95% CI 0.05–13.20); stage II: 9.77% (95% CI 0.59–19.01), and stage III: 22.31% (95% CI 6.34–38.45). The age-adjusted survival curves derived from this modeling were implemented in the web application BreCanSurvPred (https://pdocomputation.snpstats.net/BreCanSurvPred). Web applications like BreCanSurvPred can help oncologists discuss the consequences of non-adherence to prescribed ET with patientsTis work was supported by Instituto de Salud Carlos III PI18/01836 funded by FEDER funds/European Regional
Development Fund (ERDF)-a way to Build Europe-//FONDOS FEDER “una manera de hacer Europa”. We also
acknowledge the support of Agència d’Avaluació d’Universitats i Recerca (2017SGR00735) from Generalitat de
Catalunya and PGC2018-095931-B-100 (MCIU/AEI/FEDER, UE). We also thank CERCA Programme/Generalitat de Catalunya for institutional support
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess
Mama -- Càncer -- Tractament
Breast -- Cancer -- Treatment
Hormonoteràpia
Hormone therapy
Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion peer-reviewed